ENBREL Indications and Usage

Moderate to Severe Rheumatoid Arthritis

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate or used alone.

Read more about ENBREL for the treatment of moderate to severe RA

Psoriatic Arthritis

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Read more about ENBREL for the treatment of psoriatic arthritis

Ankylosing Spondylitis

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Ankylosing spondylitis (AS) is a disease that causes pain and inflammation of the joints of the spine, particularly the joints between the vertebrae and also the sacroiliac joints. In many people, joints of the arms and legs can also be affected.1,2 As the disease progresses, it can often lead the affected spinal bones to fuse together.3 Prompt diagnosis and treatment may help manage signs and symptoms of the spine and joints.4

In a medical study, ENBREL was shown to be effective at improving signs and symptoms in about 3 out of 5 adults with AS who used it. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.5

Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.5

Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children. JIA is defined as persistent arthritis in one or more joints that begins before age 16 and lasts at least 6 weeks.6 There are three main kinds of juvenile idiopathic arthritis: polyarticular, pauciarticular, and systemic-onset. ENBREL is indicated for moderately to severely active polyarticular JIA.5,6

In a medical study, ENBREL was shown to be effective in about 3 out of 4 children with JIA who used it. For these JIA patients, ENBREL has been shown to begin working in approximately 2 to 4 weeks.5,7

There have been some cases of unusual cancers reported in children and teenage patients who started using TNF blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA and psoriasis may be more likely to get lymphoma.5

 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations
Play video

Phil Mickelson: A PsA Patient's Perspective

Listen to Phil share his personal experience to gain more insight about your patients.

Play video

More than 200,000 people have used the ENBREL Support™ card to help pay for ENBREL

Learn about our program
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years